Solentim launches new workflow for single cell cloning of stem cells –

VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability

Bournemouth, UK, 23rd September 2020 / Sciad NewswireSolentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, yesterday launched a dedicated new workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs). A combination of Solentim’s VIPS™ (verified in-situ plate seeding) instrument and the new MatriClone™ matrix has been shown to give a 4 to 5-fold improvement in cloning efficiency compared with traditional limiting dilution methods (see new application note)

Over the last three years, Solentim’s VIPS has become an industry standard for single cell cloning of CHO and HEK manufacturing cell lines in combination with the company’s InstiGRO™ growth supplements. Now, the VIPS repertoire has been extended to include hiPSC cells to address the industry challenges of poor clone viability after single cell seeding, a lack of standardization for assurance between labs and for documentation of clonality. For further information watch our latest webinar.

The VIPS can deliver around 80% seeding efficiency and allows for high viability and outgrowth of stem cell colonies due to the gentle seeding method in combination with MatriClone, an animal component-free matrix used in solution at the time of seeding. The VIPS is then able to track the single cell origin and progression to a colony using daily whole well imaging and provide a Clonality Report which can be supplied to a regulator as part of an IND submission.

Mark Truesdale, CEO, Solentim, commented: “The combination of